Smiling woman sitting in front of green wall at Alkermes

News and Events

Sharing Stories of
Patients, Employees
and Communities

Featured News

November 24, 2021

Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference

November 19, 2021

Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors

November 11, 2021

Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders

See all press releases

Our Commitment to Responsibility

Corporate responsibility has always played a central role in our business and has proven even more critical during the past year as we faced some of the most pressing public health and societal issues of our time – a dynamic global pandemic, systemic racism in the U.S. and around the world, and a worsening climate change crisis. Guided by our purpose and values, we took actions to respond to these critical issues, while sharpening our focus on scientific and business excellence in our efforts to help people living with complex and difficult-to-treat diseases. Our recently published Corporate Responsibility Report expounds on these efforts.

Corporate Responsibility Reports

Portrait of woman with mask in research laboratory environment

Pandemic Drinking Habits

Alkermes worked with The Harris Poll to conduct a survey exploring drinking patterns during the COVID-19 pandemic and people’s motivations to seek help.

Learn about the survey

Cancer Trials At-a-Glance

Learn more about our ongoing clinical research program for nemvaleukin alfa, our lead immuno-oncology candidate. The investigational IL-2 variant immunotherapy is currently being studied across clinical trials evaluating intravenous and subcutaneous dosing.

View infographic

Portrait of smiling Alkermes employee smiling

Blair Jackson in Alkermes office smiling.

Building for the Future

In a recent interview with Informa Connect's Xconomy, our Chief Operating Officer, Blair Jackson, discusses our ambitions and our evolving strategy in neuroscience and oncology.

Read the article

Media Resources

Company Description

Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.